Body mass index and creatinine clearance are associated with steady-state serum concentrations of the cell damage marker S100B in renal transplant recipients

Medical Science Monitor

Volumn 16, Issue 7, 2010, Pages 318-324

  Gross, Sascha ^a   van der Heide, Jaap J Homan ^a   van Son, Willem J ^a   Gans, Reinold O B ^a   Foell, Dirk ^a   Navis, Gerjan ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic inflammation; Kidney function; Obesity; Renal transplantation

Indexed keywords

ADIPOCYTOKINE; ANTIMITOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CREATININE; PROTEIN S100B; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

ADULT; ARTICLE; BODY MASS; CELL DAMAGE; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DEATH; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT; PREDICTION; PROTEIN BLOOD LEVEL; STEADY STATE; BLOOD; CELL DEATH; MIDDLE AGED; STATISTICAL MODEL;

BIOLOGICAL MARKERS; BODY MASS INDEX; CELL DEATH; CREATININE; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; S100 PROTEINS;

EID: 77954772700     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ponton P, Rupolo GP, Marchini F et al: Quality-of-life change after kidney transplantation. Transplant Proc, 2001; 33: 1887-89.
2. Wolfe RA, Ashby VB, Milford EL et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 1999; 341: 1725-30.
3. Hariharan S, Johnson CP, Bresnahan BA et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med, 2000; 342: 605-12.
4. Opelz G, Dohler B: CTS Collaborative Transplant Study. www.ctstransplant.org Newsletter[2]. 2000
5. Aakhus S, Dahl K, Wideroe TE: Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant, 2004; 18: 596-604.
6. Kasiske BL: Cardiovascular disease after renal transplantation. Semin Nephrol, 2000; 20: 176-87.
7. Kreis HA, Ponticelli C: Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation, 2001; 71: SS5-9.
8. Frimat L, Cassuto-Viguier E, Charpentier B et al: Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Am J Transplant, 2006; 6: 2725-34.
9. Van Ree RM, Oterdoom LH, De Vries AP et al: Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients. Nephrol Dial Transplant, 2007; 22: 246-53.
10. Winkelmayer WC, Lorenz M, Kramar R et al: C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant, 2004; 4: 1148-54.
11. Hofmann MA, Drury S, Fu C et al: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 1999; 97: 889-901.
12. Sen J, Belli A: S100B in neuropathologic states: the CRP of the brain? J Neurosci Res, 2007; 85: 1373-80.
13. Portela LV, Brenol JC, Walz R et al: Serum S100B levels in patients with lupus erythematosus: preliminary observation. Clin Diagn Lab Immunol, 2002; 9: 164-66.
14. Ahmed N: Advanced glycation endproducts - role in pathology of diabetic complications. Diabetes Res Clin Pract, 2005; 67: 3-21.
15. Galli F: Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant, 2007; 22(Suppl.5): v20-36.
16. Kasiske BL, Vazquez MA, Harmon WE et al: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol, 2000; 11(Suppl.15): S1-86.
17. De Vries AP, Bakker SJL, Van Son WJ et al: Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant, 2004; 4: 1675-83.
18. Harpio R, Einarsson R: S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem, 2004; 37: 512-18.
19. De Leeuw K, Sanders JSF, Stegeman CM et al: Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis, 2005; 64: 753-59.
20. Morgenthaler NG, Struck J, Fischer-Schulz C, Bergmann A: Sensitive immunoluminometric assay for the detection of procalcitonin. Clin Chem, 2002; 48: 788-90.
21. Deanfield J, Donald A, Ferri C et al: Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens, 2005; 23: 7-17.
22. Genuth S, Alberti KG, Bennett P et al: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 2003; 26: 3160-67.
23. van der Giessen M, van den Berg AP, van der Bij W et al: Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol, 1990; 80: 56-61.
24. Roodnat JI, Mulder PG, Rischen-Vos J et al: Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation, 2001; 72: 438-44.
25. Portela LV, Tort AB, Schaf DV et al: The serum S100B concentration is age dependent. Clin Chem, 2002; 48: 950-52.
26. Ehrlich S, Salbach-Andrae H, Weiss D et al: S100B in underweight and weight-recovered patients with anorexia nervosa. Psychoneuroendocrinology, 2008; 33: 782-88.
27. Holtkamp K, Buhren K, Ponath G et al: Serum levels of S100B are decreased in chronic starvation and normalize with weight gain. J Neural Transm, 2008; 115(6): 937-40.
28. Haimoto H, Kato K, Suzuki F, Nagura H: The ultrastructural changes of S-100 protein localization during lipolysis in adipocytes. An immunoelectronmicroscopic study. Am J Pathol, 1985; 121: 185-91.
29. Netto CB, Conte S, Leite MC et al: Serum S100B protein is increased in fasting rats. Arch Med Res, 2006; 37: 683-86.
30. Jonsson H, Johnsson P, Hoglund P et al: Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth, 2000; 14: 698-701.
31. Huttunen HJ, Kuja-Panula J, Sorci G et al: Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem, 2000; 275: 40096-105.
32. Bierhaus A, Schiekofer S, Schwaninger M et al: Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes, 2001; 50: 2792-808.
33. Da Rocha AB, Schneider RF, De Freitas GR et al: Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med, 2006; 44: 1234-42.
34. Johnsson P, Backstrom M, Bergh C et al: Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality. Ann Thorac Surg, 2003; 75: 162-68.
35. Leclerc E, Fritz G, Weibel M et al: S100b and S100A6 differentially modulate cell survival by interacting with distinct rage immunoglobulin domains. J Biol Chem, 2007; 282(43): 31317-31